Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada

Infections, Papillomavirus Clinical Trial

Official title:

Post-marketing Safety Study to Assess the Risk of Spontaneous Abortion Following Administration of CERVARIX in the United States and Canada

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01290393
• Other study ID #: 114176
• Status: Terminated
• Start date: September 26, 2011
• Est. completion date: December 20, 2012

Study information

• Verified date: July 2018
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study will assess the risk of spontaneous abortion during weeks 1-19 of gestation, and other pregnancy outcomes, in an Exposed vaccinated cohort, i.e. women with last menstrual period between 30 days before and 90 days after any dose of CERVARIX, when compared to a Non-exposed vaccinated cohort, i.e. women with last menstrual period between 120 days and 18 months after the last CERVARIX or GARDASIL dose.

Description:

The present study will be conducted by the OTIS (Organization of Teratology Information Specialists) network. OTIS is a non-profit organization specialised to assess exposures during pregnancy and dedicated to providing accurate evidence-based, clinical information to patients and health care professionals about exposures during pregnancy and lactation. OTIS is based on voluntary phone calls. Women call when they have questions and concerns about risks potentially associated with any kind of exposure during pregnancy or breastfeeding, including medications, chemicals, pesticides, diseases, infections, and vaccinations.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 2
• Est. completion date: December 20, 2012
• Est. primary completion date: December 20, 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 15 Years to 25 Years

Eligibility

Inclusion Criteria:

For Exposed vaccinated cohort:

• Written informed consent, and assent in case of minors, obtained from the subject/from the parent(s)/legally acceptable representative(s) of the subject.

• Aged between, and including, 15 and 25 years of age.

• Residing within the US or Canada.

• Subjects who received at least one dose of CERVARIX.

• Gestational age at inclusion should be 19 completed weeks (i.e. 133 days of gestation) or less.

• Last menstrual period between 30 days before and 90 days after any dose of CERVARIX with a maximum of 20% of subjects with last menstrual period between 46 and 90 days after any dose of CERVARIX.

• Subjects who the Investigator believes can and will comply with the requirements of the protocol (e.g. available for phone interviews). Or subjects who the Investigator believes that parent(s)/legally acceptable representative(s) can and will comply with the requirements of the protocol.

For Non-exposed vaccinated cohort:

• Written informed consent, and assent in case of minors, obtained from the subject/from the parent(s)/legally acceptable representative(s) of the subject.

• Aged between, and including, 15 and 25 years of age.

• Residing within the US or Canada.

• Subjects who received at least one dose of CERVARIX or at least one dose of GARDASIL.

• Gestational age at inclusion should be 19 completed weeks (i.e. 133 days of gestation) or less.

• Last menstrual period between 120 days and 18 months after the last dose of CERVARIX/ GARDASIL.

• Subjects who the Investigator believes can and will comply with the requirements of the protocol (e.g. available for phone interviews). Or subjects who the Investigator believes that parent(s)/legally acceptable representative(s) can and will comply with the requirements of the protocol.

Exclusion Criteria:

For Exposed vaccinated cohort:

• Last menstrual period between 30 days before and 90 days after any GARDASIL dose.

• Ongoing pregnancy with foetus known to be non-viable.

• Ongoing pregnancy with pre-enrolment knowledge by prenatal diagnosis of a major structural defect.

• Use of any investigational or non-registered product (drug or vaccine) during the study period.

For Non-exposed vaccinated cohort:

• Ongoing pregnancy with foetus known to be non-viable.

• Ongoing pregnancy with pre-enrolment knowledge by prenatal diagnosis of a major structural defect.

• Use of any investigational or non-registered product (drug or vaccine) during the study period.

Related Conditions & MeSH terms

• Abortion, Spontaneous
• Infections, Papillomavirus

Intervention

Other:
• Data collection
Data collection from hard copy interview forms routinely used by the Organization of Teratology Information Specialists (OTIS).

Locations

Country	Name	City	State
United States	GSK Investigational Site	San Diego	California

Sponsors (2)

Lead Sponsor	Collaborator
GlaxoSmithKline	The Organization of Teratology Information Specialists

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Occurrence of spontaneous abortion during weeks 1-19 of gestation		This outcome measure will be recorded between zero and six weeks after end of pregnancy
Secondary	Occurrence of other adverse pregnancy outcomes		This outcome measure will be recorded between zero and six weeks after end of pregnancy